Bullish
Johnson & Johnson expands US availability of intraocular lens
Johnson & Johnson (JNJ) has expanded the U.S. availability of its Tecnis PureSee intraocular lens (IOL), an extended depth of focus (EDOF) lens for ca...
JNJ
--
--
--
--
Price Chart (30 Days)
Ad Space
Analyst Sentiment
Bullish (56)
Neutral (23)
Bearish (3)
Latest JNJ News
Bullish
Bullish
Johnson & Johnson Reports Strong Late-Stage Results for Rare Blood Disorder Therapy (JNJ)
Johnson & Johnson announced positive late-stage results for its therapy, IMAAVY (nipocalimab-aahu), in treating warm autoimmune hemolytic anemia, an o...
Bearish
J&J faces $32M jury award over talc-related cancer case (JNJ)
Johnson & Johnson (JNJ) has been ordered to pay $32 million by a Los Angeles jury in a talc-related cancer case. The award was granted to the family o...
Bullish
Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal
Johnson & Johnson CEO Joaquin Duato believes that curing certain cancers and transforming others into chronic diseases is a realistic goal for the nex...
Neutral
Capital International Sarl Makes New Investment in Johnson & Johnson $JNJ
Capital International Sarl acquired a new position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) during the fourth quarter, according to the...
Bullish
J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B
Johnson & Johnson (J&J) is set to acquire biotechnology startup Firefly Bio for up to $1 billion. This acquisition will give J&J access to Firefly's "...
Neutral
J&J lights up $1bn offer for pan-KRAS developer Firefly
Johnson & Johnson has agreed to acquire Firefly Bio for $1 billion in cash, bolstering its cancer drug pipeline with Firefly's degrader-antibody conju...
Bullish
M&A News: Johnson & Johnson (JNJ) Reaches a Massive $1B Deal for Firefly Bio to Expand Its Oncology Pipeline
Johnson & Johnson (JNJ) announced its acquisition of Firefly Bio for $1 billion in cash to expand its oncology pipeline. This deal will allow J&J to a...
Neutral
Johnson & Johnson to Buy Firefly Bio for $1 Billion - WSJ
Johnson & Johnson has announced its intent to acquire biotechnology company Firefly Bio for $1 billion in cash. This acquisition is strategically aime...
Bullish
J&J to buy cancer drug technology developer Firefly Bio for $1 billion
Johnson & Johnson announced its intention to acquire biotech company Firefly Bio for $1 billion in cash. This acquisition aims to expand J&J's cancer ...
Bullish
Johnson & Johnson to buy Firefly Bio for $1 billion
Johnson & Johnson (J&J) announced its intention to acquire biotech company Firefly Bio for $1 billion in cash. This acquisition aims to bolster J&J's ...
Bullish
Johnson & Johnson Stock at $233: Why Wall Street Mean Target of $253 May Still Underestimate the Pipeline
Johnson & Johnson (JNJ) stock is trading at $233, below Wall Street's mean target of $253, but TIKR's model suggests a potential target of $325 by 203...
Bullish
Los Angeles Capital Management LLC Purchases 255,236 Shares of Johnson & Johnson $JNJ
Los Angeles Capital Management LLC increased its stake in Johnson & Johnson ($JNJ) by 26.5% in the fourth quarter, purchasing 255,236 shares and bring...
Bullish
Johnson & Johnson Dividend Stock Analysis: 64 Years of Increases and Current Valuation - News and Statistics
Johnson & Johnson, a Dividend King, has maintained a 64-year streak of annual dividend increases, showcasing its resilience through significant challe...
Bullish
Johnson And Johnson ASCO 2026 Data Adds Depth To JNJ Valuation Story
Johnson & Johnson (NYSE:JNJ) presented significant clinical trial results at ASCO 2026 covering autoimmunity, oncology, and myeloma, with promising da...
Bullish
J&J wins talc-related cancer case in California (JNJ:NYSE)
A jury in Los Angeles, California found Johnson & Johnson (JNJ) not negligent in a talc-related cancer lawsuit. The lawsuit was brought by families of...
Bullish
Pinebridge Investments LLC Makes New $50.20 Million Investment in Johnson & Johnson $JNJ
Pinebridge Investments LLC has made a new investment of $50.20 million in Johnson & Johnson, acquiring 242,556 shares in the fourth quarter. This come...
Bearish
Ovarian Cancer Jury Told Johnson & Johnson Hid Asbestos Test Results from FDA
A former FDA commissioner testified in an ovarian cancer trial against Johnson & Johnson, alleging the company altered asbestos test results for its t...
Bullish
Is It Time To Reassess Johnson & Johnson (JNJ) After A 52% One-Year Surge?
Johnson & Johnson (JNJ) has seen a significant 52% one-year surge but has recently slipped slightly, prompting a reassessment of its current valuation...
Bullish
4,997 Shares in Johnson & Johnson $JNJ Bought by Total Wealth Planning & Management Inc.
Total Wealth Planning & Management Inc. initiated a new position in Johnson & Johnson (JNJ) during the fourth quarter, acquiring 4,997 shares valued a...
Research JNJ on:
Ad Space